World's Best Scientists 2026 revealed!

D-Index & Metrics

Molecular Biology

D-Index
107
Citations
54643
World Ranking
407
National Ranking
234

Biology and Biochemistry

D-Index
118
Citations
60113
World Ranking
695
National Ranking
440

C. Frank Bennett publication distribution in Molecular Biology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Molecular Biology in 2026. The highlighted bar marks where C. Frank Bennett sits on this spectrum.

47–56 publications: 7 scientists 57–66 publications: 17 scientists 67–76 publications: 65 scientists 77–86 publications: 90 scientists 87–96 publications: 125 scientists 97–106 publications: 131 scientists 107–116 publications: 162 scientists 117–126 publications: 177 scientists 127–136 publications: 158 scientists 137–146 publications: 158 scientists 147–156 publications: 146 scientists 157–166 publications: 159 scientists 167–176 publications: 131 scientists 177–186 publications: 110 scientists 187–196 publications: 112 scientists 197–206 publications: 100 scientists 207–216 publications: 89 scientists 217–226 publications: 98 scientists 227–236 publications: 74 scientists 237–246 publications: 72 scientists 247–256 publications: 63 scientists 257–266 publications: 53 scientists 267–276 publications: 54 scientists 277–286 publications: 49 scientists 287–296 publications: 52 scientists 297–306 publications: 43 scientists 307–316 publications: 46 scientists 317–326 publications: 41 scientists 327–336 publications: 42 scientists 337–346 publications: 31 scientists 347–356 publications: 28 scientists 357–366 publications: 29 scientists 367–376 publications: 26 scientists 377–386 publications: 24 scientists 387–396 publications: 24 scientists 397–406 publications: 14 scientists 407–416 publications: 13 scientists 417–426 publications: 20 scientists 427–436 publications: 12 scientists 437–446 publications: 20 scientists 447–456 publications: 11 scientists 457–466 publications: 10 scientists 467–476 publications: 14 scientists 477–486 publications: 14 scientists 487–496 publications: 10 scientists 497–506 publications: 13 scientists 507–516 publications: 13 scientists 517–526 publications: 2 scientists 527–536 publications: 4 scientists 537–546 publications: 6 scientists 547–556 publications: 8 scientists 557–563 publications: 6 scientists 564+ publications: 100 scientists
47 publications 564+

This scientist: 311 publications — 82nd percentile

82% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 564 publications or more.

C. Frank Bennett D-index placement in Molecular Biology in 2026

The chart shows the D-index (discipline H-index) distribution of Molecular Biology scientists ranked by Research.com in 2026. The highlighted bar marks where C. Frank Bennett sits on this spectrum.

40–41 D-Index: 36 scientists 42–43 D-Index: 101 scientists 44–45 D-Index: 115 scientists 46–47 D-Index: 121 scientists 48–49 D-Index: 118 scientists 50–51 D-Index: 130 scientists 52–53 D-Index: 106 scientists 54–55 D-Index: 116 scientists 56–57 D-Index: 113 scientists 58–59 D-Index: 129 scientists 60–61 D-Index: 120 scientists 62–63 D-Index: 105 scientists 64–65 D-Index: 131 scientists 66–67 D-Index: 95 scientists 68–69 D-Index: 97 scientists 70–71 D-Index: 106 scientists 72–73 D-Index: 83 scientists 74–75 D-Index: 89 scientists 76–77 D-Index: 77 scientists 78–79 D-Index: 70 scientists 80–81 D-Index: 73 scientists 82–83 D-Index: 60 scientists 84–85 D-Index: 48 scientists 86–87 D-Index: 45 scientists 88–89 D-Index: 50 scientists 90–91 D-Index: 31 scientists 92–93 D-Index: 51 scientists 94–95 D-Index: 43 scientists 96–97 D-Index: 38 scientists 98–99 D-Index: 39 scientists 100–101 D-Index: 41 scientists 102–103 D-Index: 29 scientists 104–105 D-Index: 33 scientists 106–107 D-Index: 35 scientists 108–109 D-Index: 20 scientists 110–111 D-Index: 38 scientists 112–113 D-Index: 19 scientists 114–115 D-Index: 28 scientists 116–117 D-Index: 13 scientists 118–119 D-Index: 23 scientists 120–121 D-Index: 16 scientists 122–123 D-Index: 15 scientists 124–125 D-Index: 11 scientists 126–127 D-Index: 21 scientists 128–129 D-Index: 7 scientists 130–131 D-Index: 13 scientists 132–133 D-Index: 14 scientists 134–135 D-Index: 17 scientists 136–137 D-Index: 9 scientists 138–139 D-Index: 8 scientists 140–141 D-Index: 16 scientists 142–143 D-Index: 7 scientists 144 D-Index: 7 scientists 145+ D-Index: 100 scientists
40 D-Index 145+

This scientist: 107 D-Index — 87th percentile

87% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 145 D-Index or more.

Research.com Recognitions

  • 2019 - Breakthrough Prize in Life Sciences for the development of an effective antisense oligonucleotide therapy for children with the neurodegenerative disease spinal muscular atrophy.

Overview

C. Frank Bennett is affiliated with Ionis Pharmaceuticals in the United States and has a significant body of work primarily in the fields of Biochemistry, Genetics and Molecular Biology, as well as Medicine. Their research encompasses key subfields including Molecular Biology, Genetics, Neurology, Cellular and Molecular Neuroscience, and Surgery.

The scientist's main topics of study focus on Neurogenetic and Muscular Disorders Research, RNA Research and Splicing, RNA modifications and cancer, Amyotrophic Lateral Sclerosis (ALS) Research, Genetic Neurodegenerative Diseases, Muscle Physiology and Disorders, and RNA regulation and disease.

Frank Bennett has contributed to several prominent research publications with papers appearing in high-impact journals. Notable recent papers include:

  • Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS, 2020, New England Journal of Medicine
  • Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial, 2023, Nature Medicine
  • Mechanism of STMN2 cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies, 2023, Science
  • Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial, 2021, Nature Medicine
  • Cholesterol-functionalized DNA/RNA heteroduplexes cross the blood-brain barrier and knock down genes in the rodent CNS, 2021, Nature Biotechnology

Frequent co-authors in Bennett's work include Frank Rigo, Roger Lane, Karen Ling, Don W. Cleveland, and Holly Kordasiewicz. These collaborations indicate ongoing partnerships in advancing research related to antisense oligonucleotides and neurodegenerative diseases.

The scientist has published frequently in several notable venues, including bioRxiv (Cold Spring Harbor Laboratory), Nature Medicine, Human Molecular Genetics, Nature Communications, and Nucleic Acids Research. The diversity of these platforms reflects a broad impact across multiple areas within molecular genetics and neurological research.

Best Publications

  • miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting.

    Christine Esau;Scott Davis;Susan F. Murray;Xing Xian Yu

  • The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation.

    Vidisha Tripathi;Jonathan D. Ellis;Zhen Shen;David Y. Song

  • Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy

    Richard S. Finkel;Eugenio Mercuri;Basil T. Darras;Anne M. Connolly

  • RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform

    C Frank Bennett;Eric E Swayze

  • Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43

    Magdalini Polymenidou;Clotilde Lagier-Tourenne;Kasey R. Hutt;Stephanie C. Huelga

  • MicroRNA-143 regulates adipocyte differentiation.

    Christine Esau;Xiaolin Kang;Eigen Peralta;Elaine Hanson

  • Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy

    Eugenio Mercuri;Basil T. Darras;Claudia A. Chiriboga;John W. Day

  • Antisense oligonucleotide modulation of multidrug resistance-associated protein

    Edgardo Baracchini;C. Frank Bennett;Nicholas M. Dean

  • RNA Toxicity from the ALS/FTD C9ORF72 Expansion Is Mitigated by Antisense Intervention

    Christopher J. Donnelly;Ping-Wu Zhang;Jacqueline T. Pham;Aaron R. Haeusler

  • Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study

    Richard S Finkel;Claudia A Chiriboga;Jiri Vajsar;John W Day

  • Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides.

    Richard S. Geary;Daniel Norris;Rosie Yu;C. Frank Bennett

  • Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis.

    Holly B. Kordasiewicz;Lisa M. Stanek;Edward V. Wancewicz;Curt Mazur

  • Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents: A COMPARATIVE ANALYSIS *

    Timothy A. Vickers;Seongjoon Koo;C. Frank Bennett;Stanley T. Crooke

  • Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs

    Clotilde Lagier-Tourenne;Magdalini Polymenidou;Kasey R. Hutt;Anthony Q. Vu

  • Targeting RNA Foci in iPSC-Derived Motor Neurons from ALS Patients with a C9ORF72 Repeat Expansion

    Dhruv Sareen;Jacqueline G. O’Rourke;Pratap Meera;A. K. M. G. Muhammad

  • Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model

    Yimin Hua;Kentaro Sahashi;Frank Rigo;Gene Hung

  • RNA-Targeted Therapeutics.

    Stanley T. Crooke;Joseph L. Witztum;C. Frank Bennett;Brenda F. Baker

  • Regulating Gene Expression through RNA Nuclear Retention

    Kannanganattu V. Prasanth;Supriya G. Prasanth;Zhenyu Xuan;Stephen Hearn

  • Antisense Masking of an hnRNP A1/A2 Intronic Splicing Silencer Corrects SMN2 Splicing in Transgenic Mice

    Yimin Hua;Timothy A. Vickers;Hazeem L. Okunola;C. Frank Bennett

  • Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model

    Yimin Hua;Kentaro Sahashi;Gene Hung;Frank Rigo

Frequent Co-Authors

Frank Rigo
Frank Rigo Ionis Pharmaceuticals (United States)
Nicholas M. Dean
Nicholas M. Dean Ionis Pharmaceuticals (United States)
Eric E. Swayze
Eric E. Swayze Ionis Pharmaceuticals (United States)
Adrian R. Krainer
Adrian R. Krainer Cold Spring Harbor Laboratory
Don W. Cleveland
Don W. Cleveland University of California, San Diego
David J. Ecker
David J. Ecker Ionis Pharmaceuticals (United States)
Brett P. Monia
Brett P. Monia Ionis Pharmaceuticals (United States)
David L. Spector
David L. Spector Cold Spring Harbor Laboratory
Punit P. Seth
Punit P. Seth Ionis Pharmaceuticals (United States)
Muthiah Manoharan
Muthiah Manoharan Alnylam Pharmaceuticals (United States)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Best Scientists Citing C. Frank Bennett

Trending Scientists

Recently Published Articles